XBiotech Inc.

NasdaqGS:XBIT Stock Report

Market Cap: US$194.5m

XBiotech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for XBiotech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

Aug 30
Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

XBiotech: Several Shots On Goal In Big Target Market Indications

May 24

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

May 13
Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Feb 09
We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

Oct 25
We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

Jun 16
We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

May 11
XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Mar 18
Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

Jan 08
Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

Nov 19

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as XBiotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqGS:XBIT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024N/A-33-29-28N/A
6/30/2024N/A-35-25-23N/A
3/31/2024N/A-31-22-21N/A
12/31/2023N/A-25-19-19N/A
9/30/20230-23-19-18N/A
6/30/20232-28-19-18N/A
3/31/20234-31-15-15N/A
12/31/20224-33-15-15N/A
9/30/20228-36-14-13N/A
6/30/202211-27-17-16N/A
3/31/202214-205963N/A
12/31/202118-176669N/A
9/30/202119-136671N/A
6/30/202125-127682N/A
3/31/202136-14-7-3N/A
12/31/202044-11-69-65N/A
9/30/202039677-70-69N/A
6/30/202028673-82-81N/A
3/31/202013674-75-74N/A
12/31/2019N/A669-18-18N/A
9/30/2019N/A-24-20-20N/A
6/30/2019N/A-23-19-19N/A
3/31/2019N/A-23-18-18N/A
12/31/2018N/A-21-17-17N/A
9/30/2018N/A-22-19-18N/A
6/30/2018N/A-23N/A-21N/A
3/31/2018N/A-27N/A-25N/A
12/31/2017N/A-33N/A-34N/A
9/30/2017N/A-42N/A-40N/A
6/30/2017N/A-49N/A-48N/A
3/31/2017N/A-53N/A-48N/A
12/31/2016N/A-53N/A-46N/A
9/30/2016N/A-48N/A-44N/A
6/30/2016N/A-47N/A-36N/A
3/31/2016N/A-40N/A-37N/A
12/31/2015N/A-37N/A-33N/A
9/30/2015N/A-32N/A-26N/A
6/30/2015N/A-28N/A-22N/A
3/31/2015N/A-25N/A-16N/A
12/31/2014N/A-22N/A-12N/A
9/30/2014N/A-18N/A-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if XBIT's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if XBIT's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if XBIT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if XBIT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if XBIT's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XBIT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:18
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

XBiotech Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaNOBLE Capital Markets, Inc.
Joseph CatanzaroPiper Sandler Companies